Kurt Spiteri Cornish

Sheffield Teaching Hospitals NHS Trust, London, UK.

JOURNAL REVIEWED: Current Eye Research

Latest Contribution

The effect of everolimus on retinal pigment epithelium and proliferative vitreo-retinopathy

1 August 2018 | | Retina / Uvea / Vitreous | Everolimus, mammalian target of rapamycin (mTOR), proliferative vitreoretinopathy, retinal detachment, ribosomal protein S6 (RPS6)

The principal cells involved in proliferative vitreo-retinopathy (PVR) are retinal pigment epithelial cells (RPE). Everolimus is a drug used in renal cell carcinoma which targets and inhibits a key regulatory protein in cancer (mTOR). In this study, the authors investigated...

Management of diabetic macular oedema (DMO)

1 February 2018 | | Retina / Uvea / Vitreous | Anti-VEGF therapy, Diabetic macular edema, Steroids

The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...

Steroid implants in the treatment of post-epiretinal membrane peel macular oedema

1 February 2018 | | Retina / Uvea / Vitreous | Central retinal thickness, Dexamethasone implant, Fluocinolone acetonide implant, Intravitreal steroid implants, Long-term outcome, Macular pucker surgery, Membrane peeling, Pars plana vitrectomy, Persistent macular edema

This is a retrospective review of 39 eyes of 37 patients treated with Ozurdex® (intravitreal dexamethasone implant) for persistent post-operative cystoid macular oedema (CMO) following vitrectomy and idiopathic epiretinal membrane (ERM) peeling. The 0.7mg implant was injected in each eye...